LENZ THERAPEUTICS

Topline INSIGHT Results

Phase 2C Clinical Trial NCT05294328

September 2023

Both LNZ101 and LNZ100 met all endpoints with highly significant response rates to 10 hours

	1 Hour			10 Hour		
	Vehicle	LNZ100	LNZ101	Vehicle	LNZ100	LNZ101
Primary **Percentage of subjects ≥ 3-line improvement and no loss in BCDVA ≥ 5 letters**	6%	71% p<0.0001	56% p<0.0001	4%	37% p<0.0012	48% p<0.0002
Secondary **Percentage of subjects ≥ 2-line improvement and no loss in BCDVA ≥ 5 letters**	27%	86% p<0.0001	78% p<0.0001	12%	55% p<0.0001	58% p<0.0001

Broad patient population
Mean age 56 yo (45-73)
Refractive Error -3.25D SE to +1.5D SE

Well tolerated
Improved NV without compromising DV in both low and normal light

INSIGHT trial compared LNZ100 and LNZ101 against vehicle on key variables

LNZ100

1.75% Aceclidine

- **Ready to use**
- **Preservative Free Eye Drop**

LNZ101

1.75% Aceclidine + Brimonidine

- **Extended duration**

Objective
To evaluate the safety and efficacy of LNZ101 compared with LNZ100 and vehicle in the treatment of Presbyopia

Primary Endpoint
Percentage of subjects who achieve a 3-line or greater improvement and no loss in BCDVA ≥ 5 letters at 1h

Secondary Endpoint
Percentage of subjects who achieve a 2-line or greater improvement and no loss in BCDVA ≥ 5 letters at 1h

Other Variables
Percentage of subjects who achieved a 3-line or greater improvement no loss in BCDVA ≥ 5 letters from 0.5 – 10 hours, Pupil Diameter, AEs

Broad patient population and 10 hour study

INSIGHT Trial Design



Study Design

- 5 US Sites
- 50+ Patients
- Placebo controlled
- 10 hr duration

Study Population

- Average Age: 56 (46 – 73)
- Refractive Range (-3.25D SE to +1.5D SE)
- 60%/40% Female/Male
- 60%/40% Brown Iris/Other
- Includes Post Lasik presbyopes and Pseudophakes

Pupil diameter within 1.5mm – 2mm for 10 hours



Average pupil size reduced **to ~1.6mm at 30 minutes**

Pupil size **correlates to** lines of **near vision improvement**

Average pupil size **maintained in sweet spot** of 1.5mm to 2mm **for 10 hours**

Primary 1 hour endpoint met and 10 hours superiority



p<0.0012 for all time points compared to vehicle

Extended **category leadership** for efficacy and duration for both LNZ100 and LNZ101

Rapid onset with resp. **73% and 62%** efficacy within **30 min**

Extended Duration with **significance for 10 hours,** LNZ101 statistically separates from LNZ100 at 9 hours

94% of the subjects achieved distance corrected near visual acuity of **20/40 or better**

Well **placebo-controlled** study

Secondary 1 hour endpoint met and 10 hours superiority



p<0.0012 for all time points compared to vehicle

Both LNZ100 and LNZ101 **provided clinically meaningful 2 lines** or more NV improvement **for almost all patients**

Rapid onset with resp. **92% and 78%** efficacy within **30 min**

Extended duration with **significance for 10 hours**

No impact to distance vision in normal and low light



No impact to distance vision in **normal light**

No impact to distance vision in **low light**

Well tolerated, No drug related serious adverse events

Additional INSIGHT data to be provided at upcoming industry conferences

LENZ THERAPEUTICS

Visit: LENZ-tx.com for more information